A Phase I, Randomized, Placebo-Controlled Study of LY3074828, an Anti-IL-23 Humanized Antibody
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 03 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.